table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
sarilumab sarilumab Sanofi phase 3 outside US REMAP-CAP sarilumab sarilumab Sanofi phase 3 US
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...

1 studies excluded by filtering options 1

5633 ARI-RAF (Della-Torre), 2020 1130not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons